|
US7393682B1
(en)
*
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
|
DE69434651T2
(de)
|
1993-12-07 |
2007-03-08 |
Genetics Institute, Inc., Cambridge |
Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
|
|
US6891082B2
(en)
*
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
US6656475B1
(en)
*
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
|
US7037501B2
(en)
|
2001-01-04 |
2006-05-02 |
Regents Of The University Of Minnesota |
Myostatin immnoconjugate
|
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
|
EP1790726B1
(en)
*
|
2001-02-08 |
2013-07-03 |
Wyeth LLC |
Modified and stabilized GDF propeptides and uses thereof
|
|
US6734289B2
(en)
|
2001-03-29 |
2004-05-11 |
The University Of Chicago |
Gastrokines and derived peptides including inhibitors
|
|
US7629317B2
(en)
|
2001-03-29 |
2009-12-08 |
The University Of Chicago |
Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
|
|
DE60213248T2
(de)
*
|
2001-06-05 |
2006-11-30 |
Genetics Institute, LLC, Cambridge |
Verfahren zur reinigung hochanionischer proteine
|
|
CA2453189A1
(en)
*
|
2001-07-11 |
2003-01-23 |
Ovita Limited |
Bioassay for myostatin
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
BR0307871A
(pt)
|
2002-02-21 |
2005-04-12 |
Wyeth Corp |
Proteìnas contendo domìnio de folistatina
|
|
CA2476887A1
(en)
|
2002-02-21 |
2003-09-04 |
Wyeth |
Gasp1:a follistatin domain containing protein
|
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
|
CN101287484B
(zh)
*
|
2002-12-20 |
2012-10-10 |
安姆根有限公司 |
抑制肌肉生长抑制素的结合剂
|
|
BRPI0410927A
(pt)
|
2003-06-02 |
2006-06-27 |
Wyeth Corp |
métodos terapêuticos e profiláticos para distúrbios neuromusculares
|
|
EP1732589A2
(en)
|
2004-03-26 |
2006-12-20 |
Acceleron Pharma Inc. |
Bmp-3 propeptides and related methods
|
|
JP4688483B2
(ja)
|
2004-04-15 |
2011-05-25 |
株式会社テクノネットワーク四国 |
フォリスタチン変異体ポリペプチド
|
|
US7741284B2
(en)
|
2004-05-12 |
2010-06-22 |
Acceleron Pharma Inc. |
BMP10 propeptides and related methods
|
|
US7465706B2
(en)
|
2004-06-24 |
2008-12-16 |
Acceleron Pharma Inc. |
GDF3 propeptides and related methods
|
|
EP1771470B1
(en)
|
2004-07-23 |
2013-06-26 |
Acceleron Pharma Inc. |
Actrii receptor polypeptides, methods and compositions
|
|
MX2007001118A
(es)
*
|
2004-07-29 |
2007-03-15 |
Schering Plough Ltd |
Uso de inhibidores cinasa semejante a activina 5 para modular o inhibir la actividad de miostatina llevando a acrecion incrementada del tejido magro en los animales.
|
|
AU2006232914A1
(en)
*
|
2005-03-23 |
2006-10-12 |
Wyeth |
Detection of an immune response to GDF-8 modulating agents
|
|
CA2601667A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Wyeth |
Detection of gdf-8 modulating agents
|
|
US8017576B2
(en)
|
2005-05-10 |
2011-09-13 |
The University Of Chicago |
Methods and compositions to treat mucositis
|
|
ES2534760T3
(es)
|
2005-08-19 |
2015-04-28 |
Wyeth Llc |
Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
|
|
BRPI0616923A2
(pt)
|
2005-10-06 |
2011-07-05 |
Lilly Co Eli |
anticorpos monoclonais, seus usos e composição farmacêutica
|
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
KR20190006086A
(ko)
|
2005-11-23 |
2019-01-16 |
악셀레론 파마 인코포레이티드 |
액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
|
|
CA2661836A1
(en)
|
2006-09-05 |
2008-03-13 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
|
DK2124999T3
(da)
|
2006-12-18 |
2013-01-14 |
Acceleron Pharma Inc |
Activin-actrii antagonister og anvendelser til behandling af anæmi
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
EP2111229B1
(en)
|
2007-02-01 |
2013-04-10 |
Acceleron Pharma, Inc. |
Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
|
|
TWI782836B
(zh)
|
2007-02-02 |
2022-11-01 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
|
ES2756725T3
(es)
|
2007-02-09 |
2020-04-27 |
Acceleron Pharma Inc |
Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
|
|
TWI573802B
(zh)
|
2007-03-06 |
2017-03-11 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
|
EP3243524A1
(en)
|
2007-09-18 |
2017-11-15 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
|
KR100857861B1
(ko)
*
|
2007-10-15 |
2008-09-11 |
주식회사 바이오리더스 |
Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
SMT202300222T1
(it)
|
2008-08-14 |
2023-09-06 |
Acceleron Pharma Inc |
Trappole di gdf
|
|
SG10201703067QA
(en)
|
2008-11-26 |
2017-05-30 |
Amgen Inc |
Variants Of Activin IIB Receptor Polypeptides And Uses Thereof
|
|
US8138142B2
(en)
|
2009-01-13 |
2012-03-20 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin in a patient in need thereof
|
|
BRPI1010587A2
(pt)
|
2009-06-08 |
2019-04-09 |
Acceleron Pharma Inc. |
métodos para aumentar adipócitos termogênicos
|
|
EP2440577A4
(en)
|
2009-06-12 |
2013-01-23 |
Acceleron Pharma Inc |
SHORTEN ACTRIIB FC FUSION PROTEINS
|
|
KR20180085825A
(ko)
|
2009-08-13 |
2018-07-27 |
악셀레론 파마 인코포레이티드 |
적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
|
|
CN102741276A
(zh)
*
|
2009-10-01 |
2012-10-17 |
可维塔有限公司 |
合成的肌肉抑制素肽拮抗剂
|
|
EP3818988A1
(en)
|
2009-11-03 |
2021-05-12 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
|
JP6267425B2
(ja)
|
2009-11-17 |
2018-01-24 |
アクセルロン ファーマ, インコーポレイテッド |
筋ジストロフィー治療のためのユートロフィン誘導に関するactriibタンパク質およびその改変体およびその使用
|
|
CN103298832A
(zh)
|
2010-11-08 |
2013-09-11 |
阿塞勒隆制药公司 |
Actriia结合剂及其用途
|
|
BR112014009528B1
(pt)
|
2011-10-17 |
2020-12-29 |
Acceleron Pharma, Inc. |
usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz
|
|
HK1203384A1
(en)
|
2011-12-19 |
2015-12-11 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
EP2861617A1
(en)
|
2012-06-15 |
2015-04-22 |
Pfizer Inc. |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
ES3047691T3
(en)
|
2012-08-01 |
2025-12-04 |
Ikaika Therapeutics Inc |
Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
|
|
KR20150072412A
(ko)
|
2012-10-05 |
2015-06-29 |
리겔 파마슈티칼스, 인크. |
Gdf-8 억제제
|
|
NZ707477A
(en)
|
2012-11-02 |
2019-09-27 |
Celgene Corp |
Activin-actrii antagonists and uses for treating bone and other disorders
|
|
SG10201706148WA
(en)
|
2013-02-01 |
2017-08-30 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject
|
|
HRP20251426T1
(hr)
|
2013-05-06 |
2026-01-02 |
Scholar Rock, Inc. |
Sastavi i postupci za modulaciju faktora rasta
|
|
MX388380B
(es)
|
2014-04-18 |
2025-03-19 |
Acceleron Pharma Inc |
Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
|
|
US10023621B2
(en)
|
2014-06-04 |
2018-07-17 |
Acceleron Pharma Inc. |
Follistatin-related fusion proteins
|
|
WO2015192111A1
(en)
|
2014-06-13 |
2015-12-17 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ulcers
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
EP3221318B1
(en)
|
2014-11-21 |
2021-08-25 |
Rigel Pharmaceuticals, Inc. |
Fused imidazole derivatives as tgf-beta inhibitors
|
|
JP2018501307A
(ja)
|
2014-12-03 |
2018-01-18 |
セルジーン コーポレイション |
アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
CN107531666A
(zh)
|
2015-02-20 |
2018-01-02 |
里格尔药品股份有限公司 |
Gdf‑8抑制剂
|
|
ES2789331T3
(es)
|
2015-03-02 |
2020-10-26 |
Rigel Pharmaceuticals Inc |
Inhibidores de TGF-beta
|
|
US11021468B2
(en)
|
2015-04-01 |
2021-06-01 |
Rigel Pharmaceuticals, Inc. |
TGF-ß inhibitors
|
|
ES2918924T3
(es)
|
2015-04-01 |
2022-07-21 |
Rigel Pharmaceuticals Inc |
Inhibidores de TGF-beta
|
|
US10227392B2
(en)
|
2015-04-06 |
2019-03-12 |
Acceleron Pharma Inc. |
ALK7:ActRIIB heteromultimers and uses thereof
|
|
CN107849114B
(zh)
|
2015-04-06 |
2021-08-20 |
阿塞勒隆制药公司 |
单臂i型和ii型受体融合蛋白和其用途
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
PT3286206T
(pt)
|
2015-04-22 |
2021-04-01 |
Biogen Ma Inc |
Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
|
|
US11123430B2
(en)
|
2015-11-04 |
2021-09-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
CA3005975A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
|
WO2017177013A1
(en)
|
2016-04-06 |
2017-10-12 |
Acceleron Pharma Inc. |
Alk7 antagonists and uses thereof
|
|
HRP20210694T1
(hr)
|
2016-07-15 |
2021-09-17 |
Acceleron Pharma, Inc. |
Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije
|
|
PL3490582T3
(pl)
|
2016-07-27 |
2024-09-23 |
Acceleron Pharma Inc. |
Kompozycje do zastosowania w leczeniu mielofibrozy
|
|
BR112019006993A2
(pt)
|
2016-10-05 |
2019-09-03 |
Acceleron Pharma Inc |
heteromultímeros de alk4:actriib e usos dos mesmos
|
|
JP7280182B2
(ja)
|
2016-10-05 |
2023-05-23 |
アクセルロン ファーマ インコーポレイテッド |
バリアントActRIIBタンパク質およびその使用
|
|
JP2019529509A
(ja)
|
2016-10-05 |
2019-10-17 |
アクセレロン ファーマ インコーポレーテッド |
腎臓疾患を治療するための組成物および方法
|
|
JOP20190085A1
(ar)
|
2016-10-20 |
2019-04-17 |
Biogen Ma Inc |
طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
|
|
CA3124415A1
(en)
|
2018-12-21 |
2020-06-25 |
Northwestern University |
Use of annexins in preventing and treating muscle membrane injury
|
|
US20220062299A1
(en)
|
2018-12-26 |
2022-03-03 |
Northwestern University |
Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
|
|
EP3995153A4
(en)
*
|
2019-06-26 |
2023-11-22 |
KNC Laboratories Co., Ltd. |
Nucleic acid drug suppressing production of myostatin gene mrna
|